Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lufax Holding Ltd (LU) vs TG Therapeutics Inc (TGTX) Price & Performance

Lufax Holding LtdTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Lufax Holding Ltd vs TG Therapeutics Inc — how do they compare? Lufax Holding Ltd trades at $1.52 (market cap $2.41B), while TG Therapeutics Inc trades at $49.66 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 3.2× Lufax Holding Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.

LUTGTX
Market Cap
$2.41B$7.64B
Sector
TechnologyHealth
52-Week High
$4.40$59.06
52-Week Low
$1.23$26.94
Enterprise Value
$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lufax Holding Ltd

Lufax Holding Ltd (LU) trades at $1.53, down 7.83% over the past day, reflecting ongoing investor caution amid financial losses and legal challenges. The stock shows a bullish technical signal with moving averages supporting an uptrend, but fundamentals remain weak with a net loss of $2.1 billion in 2025 and negative profit margins. Recent news highlights board changes and a securities class action lawsuit, adding to uncertainty.

The outlook for LU is clouded by persistent unprofitability and legal risks, though low valuation ratios like P/S of 0.39 and P/B of 0.11 may attract value investors. Analysts are predominantly bullish with 69% buy ratings, but the stock faces significant headwinds from operational losses and regulatory scrutiny, requiring careful risk assessment for any investment.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.

Returns comparison

Trailing returns across standard periods

About Lufax Holding Ltd

Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.

Read more on LU

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX